TaiAn Technologies Corporation

Aprinoia Therapeutics Inc. is a clinical-stage biotechnology company focused on developing innovative imaging-based diagnostic tools and therapies for neurological diseases, particularly Alzheimer's disease and tauopathies. Established in 2015 and headquartered in Taipei, Taiwan, with additional facilities in China and Japan, the company specializes in creating diagnostic tracers, including 18F-PM-PBB3 for tau positron-emission tomography (PET) imaging, which aids in identifying tauopathies and supports the development of corresponding treatments. Aprinoia Therapeutics aims to enhance the detection, progression monitoring, and treatment of neurodegenerative conditions such as Alzheimer's, Parkinson's, and dementia through its advanced diagnostic and therapeutic platforms, ultimately striving to improve patient outcomes and brain health.

Sapience Therapeutics, Inc. is a biotechnology company dedicated to the discovery and development of peptide-based therapeutics aimed at treating high mortality cancers. Founded in 2015 and headquartered in Harrison, New York, the company focuses on advancing innovative treatments for major unmet medical needs, particularly glioblastoma multiforme (GBM), the most aggressive form of brain cancer. Its lead product, ST101, functions as an inhibitor of C/EBPß, a transcription factor that is often overexpressed in various cancers and plays a role in cellular differentiation, tumor survival, and proliferation. ST101 targets and reduces the expression of several genes and proteins linked to cancer cell survival and growth, inducing selective cytotoxicity across multiple tumor types, including breast cancer, melanoma, prostate cancer, GBM, lung cancer, and acute myeloid leukemia. Through its research, Sapience Therapeutics aims to translate scientific advancements into effective therapies that address oncogenic and immune dysregulation in cancer.